Freitag, 5. März 2021
Navigation öffnen
Anzeige:
Keytruda Pantumor
Keytruda Pantumor
JOURNAL ONKOLOGIE – STUDIE

BENEFIT Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Rekrutierend

NCT-Nummer:
NCT02999074

Studienbeginn:
Januar 2016

Letztes Update:
09.02.2021

Wirkstoff:
-

Indikation (Clinical Trials):
Breast Neoplasms

Geschlecht:
Frauen

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
German Cancer Research Center

Collaborator:
University Hospital Heidelberg

Kontakt

Studienlocations (1 von 1)

National Center for Tumor Diseases (NCT)
69120 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Martina E Schmidt, Dr.
Phone: +49 6221 42 2220
E-Mail: m.schmidt@dkfz.de

Karen Steindorf, Prof. Dr.
Phone: +49 6221 42 2351
E-Mail: k.steindorf@dkfz.de
» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

The BENEFIT-Study is a randomized controlled 3-arm intervention trial investigating the

currently discussed hypothesis that exercise concomitant to chemotherapy (CTx) may have a

beneficial effect on cancer prognosis by boosting the anti-tumoral effect of the cytostatics

or by enhancing therapy compliance. This hypothesis is based on pre-clinical and exploratory

clinical trials. Breast cancer patients scheduled for neoadjuvant CTx will be randomized to

either a resistance training or an aerobic training concomitant to the neoadjuvant CTx, or a

waiting list control group that will get no exercise intervention during neoadjuvant CTx

(i.e. usual care) but will exercise after breast surgery. The primary study endpoint is the

tumor size. Further, the effects of resistance and aerobic exercise on the

clinical-pathologic stage (CPS-EG) score, the pathological complete response (pCR),

tolerability and compliance to CTx, physical fitness, patient reported outcomes such as

fatigue, sleep problems, quality of life, depressive symptoms, anxiety and pain, as well as

cognitive function, and selected biomarkers will be investigated.

A confirmation of the study hypothesis would be a strong argument for patients to engage in

exercise as early as during neoadjuvant CTx. The trial will also provide evidence-based

guidance for patients regarding type and timing of training.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Women ≥ 18 years of Age

- Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by

core biopsy

- Scheduled for neoadjuvant CTx (but not yet started)

- Confirmed hormone receptor and Her2 status

- Sufficient German language skills

- Willing to train at the exercise facilities twice per week

Exclusion Criteria:

- Any physical or mental conditions that would hamper the adherence to the training

programs or the completion of the study procedures

- Engaging in systematic intense exercise training (at least 1h twice per week)

Studien-Rationale

Primary outcome:

1. Tumor size (Time Frame - change from baseline (before start of neoadjuvant chemotherapy) to breast surgery):
percentage of change from the maximal diameter of the lesion assessed before neoadjuvant chemotherapy (by mammography or sonography) to the maximal diameter of the tumor assessed after neoadjuvant chemotherapy at breast surgery



Secondary outcome:

1. CPS-EG score (Time Frame - at breast surgery):
The Clinical-Pathologic Stage (CPS-EG) score combines clinical tumor stage prior to neoadjuvant therapy (CS), pathological tumor stage after neoadjuvant treatment (PS), estrogen receptor status (E) and grading (G). It has been shown to be a valid prognostic factor to discriminate among patient subgroups with respect to survival after neoadjuvant CTx.

2. pCR (Time Frame - at breast surgery):
The Pathological Complete Response (pCR) is defined as ypT0/is ypN0 and has been consistently demonstrated to be a good prognostic factor for long-term benefit from neoadjuvant CTx.

3. Fatigue Assessment Questionnaire (FAQ) (Time Frame - at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery):
Validated 20-item multidimensional self-assessment questionnaire to assess the physical, affective, and cognitive dimension of cancer-related fatigue

4. EORTC QLQ-C30 / BR23 (Time Frame - at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery):
Validated 30-item self-assessment questionnaire to assess quality of life aspects.

5. Patient Health Questionnaire for Depression and Anxiety (PHQ-4) (Time Frame - at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery):
A validated 4-item screener for depression and anxiety.

6. Pittsburgh Sleep Quality Index (PSQI) (Time Frame - at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery):
Validated questionnaire to assess sleep quality and sleep problems.

7. Spiroergometry (VO2max) (Time Frame - at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery)

8. Isometric and isokinetic muscle strength measured by ISOMED 2000 (Time Frame - at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery)

9. Body mass index (Time Frame - at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery)

10. Self-developed physical activity questionnaire including type, duration, frequency and intensity of sports, cycling,and walking (Time Frame - Follow-up (6 months and 12 months after breast surgery))

11. Cognitive function - HVLT-R (Time Frame - at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery):
Hopkins Verbal Learning Test - Revised (HVLT-R)

12. Cognitive function - TMT (Time Frame - at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery):
Trail Making Test

13. Cognitive function - COWA (Time Frame - at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery):
Controlled Oral Word Association

14. Sleep quality (Time Frame - at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery):
Measured with ActiGraph (accelerometry)

15. Sleep efficiency (Time Frame - at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery):
Measured with ActiGraph (accelerometry)

Studien-Arme

  • Active Comparator: Resistance exercise
  • Active Comparator: Aerobic exercise
  • Other: Waitlist control

Geprüfte Regime

  • Resistance exercise:
    The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
  • Aerobic exercise:
    The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
  • Usual care during neoadjuvant chemotherapy/Exercise after surgery:
    The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Internetplattform „Stärker gegen Krebs“: ergänzende, stärkende Angebote für Krebspatienten in Corona-Zeiten

Internetplattform „Stärker gegen Krebs“: ergänzende, stärkende Angebote für Krebspatienten in Corona-Zeiten
© Frantab - stock.adobe.com

Krebspatienten mit einem geschwächten Immunsystem haben laut DGHO (Deutsche Gesellschaft für Hämatologie und Onkologie) und Robert Koch-Institut ein erhöhtes Risiko für einen schweren Verlauf der Erkrankung Covid-19. Umso sinnvoller sind begleitende Maßnahmen zur Stärkung des körpereigenen Abwehrsystems, die gleichzeitig das physische und psychische Wohlbefinden und damit die Lebensqualität erhöhen. Das Portal...

Bis zu 40 Prozent mehr Leberkarzinome entdecken – dank Ultraschallverfahren mit kombinierten Bluttests

Bis zu 40 Prozent mehr Leberkarzinome entdecken – dank Ultraschallverfahren mit kombinierten Bluttests
© Sebastian Kaulitzki / fotolia.com

In Deutschland erkranken jährlich circa 9000 Menschen an Leberkrebs – und die Häufigkeit der Erkrankung nimmt deutlich zu. In den vergangenen 35 Jahren hat sich die Zahl der Neuerkrankungen verdoppelt. Ein gängiges Verfahren zur Diagnose dieser Erkrankung ist die Ultraschalluntersuchung: Mithilfe der modernen Sonografie lässt sich gutartiges Gewebe sehr exakt von bösartigem unterscheiden. Wenn die Ultraschalldiagnostik mit speziellen Bluttests kombiniert wird,...

Gesundheitliche Beschwerden nicht auf die leichte Schulter nehmen

Gesundheitliche Beschwerden nicht auf die leichte Schulter nehmen
Alexander Raths / Fotolia.com

Arzttermine aus Furcht vor dem Coronavirus auf die lange Bank schieben? Davon rät der Krebsinformationsdienst des Deutschen Krebsforschungszentrums ab. Symptome und Schmerzen sollten ernst genommen und vom Arzt abgeklärt werden. In den meisten Fällen wird es sich nicht um eine schwerwiegende Erkrankung wie Krebs handeln. Wenn aber doch, dann ist es besser, sie möglichst früh zu erkennen und, wenn nötig, sofort zu behandeln – dies erhöht die...

Hufeland-Preis ehrt Initiatoren eines bundesweiten Kita-Sonnenschutzprojekts zur Krebsprävention

Hufeland-Preis ehrt Initiatoren eines bundesweiten Kita-Sonnenschutzprojekts zur Krebsprävention
© drubig-photo / Fotolia.com

Prof. Eckhard Breitbart, Vorsitzender der Arbeitsgemeinschaft für Dermatologische Prävention e.V. (ADP), Dr. Nadja Seidel und Dr. Friederike Stölzel, Leiterinnen des Präventionszentrums des Nationalen Centrums für Tumorerkrankungen Dresden (NCT/UCC) sind mit dem Hufeland-Preis des Kuratoriums der Stiftung Hufeland-Preis ausgezeichnet worden. Sie erhielten den mit 20.000 Euro dotierten Preis für Präventivmedizin für ihr bundesweites Sonnenschutz-Projekt...